98% Andrographis Paniculata Supplement Powder Anti Cancer With HPLC Test

Herbal Plant Extract Anti-cancer Andrographolide of Andrographis Paniculate Extract

Plant Source of Andrographis Paniculate Extract:

Andrographis paniculata is widely cultivated in South of China, where it has been traditionally used to treat infections and some diseases. Mostly the leaves and roots were used for medicinal purposes. The whole plant is also used in some cases.

Andrographis paniculata grows erect to a height of 30–110 cm (12–43 in) in moist, shady places. The slender stem is dark green, squared in cross-section with longitudinal furrows and wings along the angles. The lance-shaped leaves have hairless blades measuring up to 8 cm (3.1 in) long by 2.5 cm (0.98 in). The small flowers are borne in spreading racemes. The fruit is a capsule around 2 cm (0.79 in) long and a few millimeters wide. It contains many yellow-brown seeds.

The Info of Andrographolide of Andrographis Paniculate Extract:

Andrographolide is a labdane diterpenoid that has been isolated from the stem and leaves of Andrographis paniculata

CAS No.: 5508-58-7

Molecular Formula:C20H30O15

Molecular Weight: 350.45

Basic Info of Andrographis Paniculate Extract:

Applications of Andrographis Paniculate Extract:

Andrographolide treatment inhibited the in vitro proliferation of different tumor cell lines, representing various types of cancers. The compound exerts direct anticancer activity on cancer cells by cell-cycle arrest at G0/G1 phase through induction of cell-cycle inhibitory protein p27 and decreased expression of cyclin-dependent kinase 4 (CDK4).

Immunostimulatory activity of andrographolide is evidenced by increased proliferation of lymphocytes and production of interleukin-2. Andrographolide also enhanced the tumor necrosis factor-alpha production and CD marker expression, resulting in increased cytotoxic activity of lymphocytes against cancer cells, which may contribute for its indirect anticancer activity. The in vivo anticancer activity of the compound is further substantiated against B16F0 melanoma syngenic and HT-29 xenograft models. These results suggest that andrographolide is an interesting pharmacophore with anticancer and immunomodulatory activities and hence has the potential for being developed as a cancer therapeutic agent.